+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hemophilia"

Haematology Diagnostics Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Haematology Diagnostics Market - Forecasts from 2024 to 2029

  • Report
  • April 2024
  • 121 Pages
  • Global
From
Cell and Gene Therapies in Hemophilia A & B - Product Thumbnail Image

Cell and Gene Therapies in Hemophilia A & B

  • Report
  • February 2024
  • 37 Pages
  • Global
From
Disease Analysis: Hemophilia - Product Thumbnail Image

Disease Analysis: Hemophilia

  • Report
  • June 2021
  • 102 Pages
  • Global
From
Loading Indicator

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing. The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place. Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more